SRRK · Insider Trading
Scholar Rock Holding Corporation Common Stock
Every open-market purchase and sale reported by SRRK officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-25 | Keith Woods | Chief Operating Officer | G | −48,034 | — |
| 2026-09-23 | David Hallal | Chief Executive Officer | G | −36,652 | — |
| 2026-07-06 | Jeffrey S. Flier | Director | Sell | −3,053 | −$164.49K |
| 2026-07-06 | Joshua Reed | Director | Sell | −3,053 | −$164.07K |
| 2026-07-06 | Katie Peng | Director | Sell | −5,446 | −$293.40K |
| 2026-07-06 | Kristina Burow | Director | Sell | −3,053 | −$164.06K |
| 2026-07-06 | Michael Gilman | Director | Sell | −2,544 | −$137.06K |
| 2026-06-08 | Srinivas Akkaraju | Director | A | +6,839 | — |
| 2026-06-08 | Michael Gilman | Director | A | +6,839 | — |
| 2026-06-08 | Kristina Burow | Director | A | +6,839 | — |
| 2026-06-08 | Richard Brudnick | Director | A | +6,839 | — |
| 2026-06-08 | Jeffrey S. Flier | Director | A | +6,839 | — |
| 2026-06-08 | Katie Peng | Director | A | +6,839 | — |
| 2026-06-08 | Joshua Reed | Director | A | +6,839 | — |
| 2026-04-24 | Kristina Burow | Director | M | +89,800 | +$820.32K |
| 2026-04-20 | Akshay Vaishnaw | President of R&D | Sell | −12,246 | −$607.09K |
| 2026-04-20 | Keith Woods | Chief Operating Officer | Sell | −10,220 | −$506.65K |
| 2026-04-20 | Vikas Sinha | Chief Financial Officer | Sell | −10,410 | −$516.07K |
| 2026-04-20 | David Hallal | Chief Executive Officer | Sell | −30,615 | −$1.52M |
| 2026-02-25 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −8,484 | −$399.35K |
| 2026-02-19 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sell | −4,157 | −$193.42K |
| 2026-02-19 | Caryn Parlavecchio | CHRO | Sell | −9,035 | −$420.38K |
| 2026-02-19 | Junlin Ho | GENERAL COUNSEL | Sell | −9,580 | −$445.74K |
| 2026-02-19 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −7,989 | −$371.71K |
| 2026-02-11 | Keith Woods | Chief Operating Officer | A | +47,021 | — |
| 2026-02-11 | Caryn Parlavecchio | Chief Human Resources Officer | A | +29,258 | — |
| 2026-02-11 | Junlin Ho | General Counsel | A | +36,572 | — |
| 2026-02-11 | Vikas Sinha | Chief Financial Officer | A | +47,021 | — |
| 2026-02-11 | David Hallal | Chief Executive Officer | A | +128,004 | — |
| 2026-02-11 | Mo Qatanani | Chief Scientific Officer | A | +29,258 | — |
| 2026-02-11 | Jing L. Marantz | Chief Medical Officer | A | +34,482 | — |
| 2026-02-11 | Akshay Vaishnaw | President of R&D | A | +47,021 | — |
| 2026-02-06 | Invus Global Management, LLC | 10%+ Owner | X | +4,725,024 | +$34.73M |
| 2026-01-23 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −14,898 | −$695.94K |
| 2026-01-21 | Caryn Parlavecchio | CHRO | Sell | −6,600 | −$293.55K |
| 2026-01-21 | Junlin Ho | GENERAL COUNSEL | Sell | −8,016 | −$356.53K |
| 2026-01-21 | Jing L. Marantz | CHIEF MEDICAL OFFICER | Sell | −5,798 | −$257.88K |
| 2026-01-21 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −8,406 | −$373.88K |
| 2026-01-16 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | MIXED | — | −$349.65K |
| 2026-01-15 | Vikas Sinha | Chief Financial Officer | Sell | −16,755 | −$715.44K |
| 2026-01-15 | Keith Woods | Chief Operating Officer | Sell | −16,746 | −$715.05K |
| 2026-01-15 | David Hallal | Chief Executive Officer | Sell | −57,450 | −$2.45M |
| 2026-01-15 | Akshay Vaishnaw | President of R&D | Sell | −20,438 | −$872.70K |
| 2025-12-18 | Katie Peng | Director | Sell | −1,006 | −$44.35K |
| 2025-12-16 | Srinivas Akkaraju | Director | MIXED | +1,094,403 | +$9.01M |
| 2025-12-05 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | MIXED | — | −$3.28M |
| 2025-10-09 | David Hallal | Chief Executive Officer | G | −205,000 | — |
| 2025-10-07 | Srinivas Akkaraju | Director | Buy | +500,439 | +$18.81M |
| 2025-09-24 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −3,353 | −$102.85K |
| 2025-09-17 | Mo Qatanani | CHIEF SCIENTIFIC OFFICER | Sell | −3,178 | −$106.53K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Raymond Debbane | 10%+ Owner | 11,051,166 | $473.21M |
| Invus Global Management, LLC | 10%+ Owner | 10,825,013 | $463.53M |
| Invus Public Equities, L.P. | 10%+ Owner | 9,700,005 | $415.35M |
| Kristina Burow | Director | 2,461,316 | $105.39M |
| David Hallal | Chief Executive Officer | 1,639,034 | $70.18M |
| Akshay Vaishnaw | President of R&D | 630,542 | $27.00M |
| Keith Woods | Chief Operating Officer | 620,055 | $26.55M |
| Vikas Sinha | Chief Financial Officer | 619,856 | $26.54M |
| Srinivas Akkaraju | Director | 558,009 | $23.89M |
| Jay T. Backstrom | CHIEF EXECUTIVE OFFICER | 425,561 | $18.22M |
| Junlin Ho | GENERAL COUNSEL | 241,545 | $10.34M |
| Edward H Myles | COO & CFO | 205,552 | $8.80M |
| Caryn Parlavecchio | CHRO | 169,087 | $7.24M |
| Jing L. Marantz | CHIEF MEDICAL OFFICER | 126,012 | $5.40M |
| Mo Qatanani | CHIEF SCIENTIFIC OFFICER | 98,645 | $4.22M |
| Erin Moore | Interim PFO and PAO | 82,609 | $3.54M |
| Tracey Sacco | Chief Commercial Officer | 71,750 | $3.07M |
| Michael Gilman | Director | 59,554 | $2.55M |
| Katie Peng | Director | 34,301 | $1.47M |
| Jeffrey S. Flier | Director | 27,871 | $1.19M |
| Richard Brudnick | Director | 21,896 | $937.59K |
| Joshua Reed | Director | 20,466 | $876.35K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the SRRK quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.